| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yi Jiang, Ke Su, Han Li, Chenjie Wang, Zhenying Wu, Jiali Chen, Zhiyao Zhang, Kun He, Yunwei Ha. Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study. Investigational new drugs. 2024-12-17. PMID:39690337. |
among the 30 assessable patients (patients treated according to the trial protocol), the median overall survival (mos) and median progression-free survival (mpfs) for the therapy comprising envafolimab alongside lenvatinib were 18.5 months (95% ci 13.2-23.8) and 9.4 months (95% ci 1.6-15.6), respectively. |
2024-12-17 |
2024-12-21 |
Not clear |
| Tianran Chen, Meng Xu, Jiajun Xu, Xianbao Zhan, Yingyi Zhang, Mingzhen Ying, Meihong W. The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer. Molecular and clinical oncology. vol 22. issue 1. 2024-12-06. PMID:39640912. |
the median (m)pfs in the overall population was 7.1 months, with a 95% confidence interval (ci) of 6.0-8.2 months and the median overall survival (mos) was 11.3 months, with a 95% ci of 4.5-18.2 months. |
2024-12-06 |
2024-12-08 |
human |
| Ofir Wolach, Itai Levi, Boaz Nachmias, Sigal Tavor, Irina Amitai, Yishai Ofran, Chezi Ganzel, Tsila Zuckerman, Doaa Okasha, Ilana Hellmann, Tamar Tadmor, Najib Dally, Jonathan Canaani, Galia Stemer, Moshe Grunspan, Adi Jacob Berger, Neta Frankel, Jenia Berelovich, Alexandra Bleterman, Moran Barak, Raanan Cohen, Yakir Mosh. Trial eligibility, treatment patterns and outcome for venetoclax-based therapy in AML: a prospective cohort study. Blood advances. 2024-12-05. PMID:39637307. |
at a median follow-up of 22.5 months (range 0.1-43), median overall-survival (mos) was 11.7 months (95% confidence interval [ci] 9.9,15.4). |
2024-12-05 |
2024-12-08 |
Not clear |
| Alexander Maurer, Giulio Clerici, Jan A Schaab, Phil F Cheng, Daniela Mihic-Probst, Cäcilia Mader, Michael Messerli, Martin W Huellner, Reinhard Dummer, Florentia Dimitrio. Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study. Clinical and experimental medicine. vol 24. issue 1. 2024-10-01. PMID:39352553. |
in the ipilimumab/nivolumab group, median pfs (mpfs) was 2.9 months (95% ci 2.2-28.6) and mos 28.9 months (95% ci 12.7-nr). |
2024-10-01 |
2024-10-03 |
Not clear |
| Alexander Maurer, Giulio Clerici, Jan A Schaab, Phil F Cheng, Daniela Mihic-Probst, Cäcilia Mader, Michael Messerli, Martin W Huellner, Reinhard Dummer, Florentia Dimitrio. Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study. Clinical and experimental medicine. vol 24. issue 1. 2024-10-01. PMID:39352553. |
in the tebentafusp group, mpfs was 2.7 months (95% ci 2.2-3) and mos 18.6 months (95% ci 11.5-nr). |
2024-10-01 |
2024-10-03 |
Not clear |
| Xiao Han, Jun Guo, Lingyu Li, Yong Huang, Xue Meng, Linlin Wang, Hui Zhu, Xiangjiao Meng, Qian Shao, Xing Li, Yan Zhang, Jin Wang, Yanhua Chen, Yingjie Zhang, Yiru Chen, Changbin Zhu, Zhehai Wan. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial. Signal transduction and targeted therapy. vol 9. issue 1. 2024-09-15. PMID:39278918. |
the mos was 13.4 months (95% ci: 11.8-nr), with a 12-month survival rate of 62.2%. |
2024-09-15 |
2024-09-18 |
Not clear |
| Alessandra Ferro, Matteo Sepulcri, Marco Schiavon, Elena Scagliori, Edoardo Mancin, Francesca Lunardi, Gisella Gennaro, Stefano Frega, Alessandro Dal Maso, Laura Bonanno, Chiara Paronetto, Francesca Caumo, Fiorella Calabrese, Federico Rea, Valentina Guarneri, Giulia Pasell. The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. Cancers. vol 14. issue 22. 2024-09-07. PMID:36428792. |
at the time of analyses 140 patients (46.5%) were alive and the median os (mos) was 44.7 months (95% ci: 38.4−51.0). |
2024-09-07 |
2024-09-09 |
Not clear |
| Alessandra Ferro, Matteo Sepulcri, Marco Schiavon, Elena Scagliori, Edoardo Mancin, Francesca Lunardi, Gisella Gennaro, Stefano Frega, Alessandro Dal Maso, Laura Bonanno, Chiara Paronetto, Francesca Caumo, Fiorella Calabrese, Federico Rea, Valentina Guarneri, Giulia Pasell. The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. Cancers. vol 14. issue 22. 2024-09-07. PMID:36428792. |
the mrfs of the unresectable population was 16.3 months (95% ci: 11.48−21.12), with a significant difference among subgroups (p = 0.030) in favour of patients who underwent the pacific-regimen; while the mos was 46.5 months (95% ci: 26.46−66.65), with a significant difference between two subgroups (p = 0.003) in favour of consolidation immunotherapy. |
2024-09-07 |
2024-09-09 |
Not clear |
| Meifang Li, Cheng Lin, Jinghui Lin, Shijie Chen, Lihong Weng, Zhiyong H. Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure. Oncology letters. vol 28. issue 5. 2024-09-05. PMID:39233818. |
the total cohort had a median progression-free survival (mpfs) of 5.2 months (95% ci, 4.077-6.323 months) and a median overall survival (mos) of 18.3 months (95% ci, 12.932-23.668 months). |
2024-09-05 |
2024-09-08 |
Not clear |
| Margarita Romeo, Marta Gil-Martín, Lydia Gaba, Iris Teruel, Álvaro Taus, Claudia Fina, Maria Masvidal, Paola Murata, Julen Fernández-Plana, Alejandro Martínez, Cristina Pérez, Yolanda García, Valerie Rodriguez, Sara Cros, Marta Parera, Montserrat Zanui, Silvia Catot, Beatriz Pardo, Andrea Plaja, Anna Esteve, Maria Pilar Barretina-Ginest. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting. Cancers. vol 14. issue 18. 2024-09-04. PMID:36139574. |
of those, 74 were treated with subsequent platinum regimens, with the following results: orr of 41.9%, median pfs (mpfs) of 6.6 months (95% ci 6−9.2), and median os (mos) of 20.6 months (95% ci 13.6−28.9). |
2024-09-04 |
2024-09-06 |
Not clear |
| Margarita Romeo, Marta Gil-Martín, Lydia Gaba, Iris Teruel, Álvaro Taus, Claudia Fina, Maria Masvidal, Paola Murata, Julen Fernández-Plana, Alejandro Martínez, Cristina Pérez, Yolanda García, Valerie Rodriguez, Sara Cros, Marta Parera, Montserrat Zanui, Silvia Catot, Beatriz Pardo, Andrea Plaja, Anna Esteve, Maria Pilar Barretina-Ginest. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting. Cancers. vol 14. issue 18. 2024-09-04. PMID:36139574. |
analysis of these 74 patients according to brca status showed that pfis for brca mutant and non brca-mutant patients were 13.6 [iqr11.2−22.2] and 10.3 [iqr 7.4−14.9] months, respectively (p = 0.010); orr were 40.0% versus 43.6%, respectively; rates of progression (as best response) to subsequent platinum were 45.7% versus 17.9%, respectively (p = 0.004); mpfs and mos were 3.5 (95% ci 2.5−8.6) versus 7.5 months (95% ci 6.5−10.1, p = 0.03), and 16.4 (95% ci 9.3−27.5) versus 24.2 months (95% ci 17.2−nr, p = 0.036), respectively. |
2024-09-04 |
2024-09-06 |
Not clear |
| Fiorenza Ferrari, Federico Sodi, Fabiana Madotto, Eleonora Carlesso, Gaetano Florio, Maria Rosa Pelliccia, Dario Laquintana, Alberto Bisesti, Alessandra Piatti, Matteo Letzgus, Navpreet Tiwana, Alessandro Jachetti, Marta Mancarella, Danilo Cereda, Olivia Leoni, Catia Rosanna Borriello, Laura Chiappa, Marcello Sottocorno, Giorgio Costantino, Alberto Zanella, Giacomo Grassell. Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting. Internal and emergency medicine. 2024-07-23. PMID:39042210. |
mos incidence rate was 278/100,000 doses (95% confidence interval (ci) 268-289). |
2024-07-23 |
2024-07-25 |
human |
| Anna M Czarnecka, Paulina Chmiel, Piotr J Błoński, Tomasz Świtaj, Paweł Rogala, Sławomir Falkowski, Hanna Koseła-Paterczyk, Paweł Teterycz, Tadeusz Morysiński, Mateusz Spałek, Michał Wągrodzki, Piotr Rutkowsk. Real-world outcomes of metastatic clear cell sarcoma sequential chemotherapy. Journal of chemotherapy (Florence, Italy). 2024-07-08. PMID:38973299. |
the median os from first-line palliative chemotherapy was 8.2 months (95% ci: 6.2-14), and the second-line palliative chemotherapy mos was 4.6 months (95% ci: 3.9-na). |
2024-07-08 |
2024-07-11 |
Not clear |
| Andrew Tam, Colton Ladbury, Ari Kassardjian, Badri Modi, Heather McGee, Laleh Melstrom, Kim Margolin, Yan Xing, Arya Amin. Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma. Cancers. vol 16. issue 11. 2024-06-19. PMID:38893072. |
with a median follow-up of 10.5 months [mos] (range 1.0-58.7 mos), we found an improvement in pfs with tvec and rt in the same region compared to different regions, which were 6.4 mos (95% ci, 2.4-nr mos) and 2.8 mos (95% ci, 0.7-4.4 mos), respectively; |
2024-06-19 |
2024-06-21 |
Not clear |
| Huizi Sha, Fan Tong, Jiayao Ni, Yi Sun, Yahui Zhu, Liang Qi, Xiaoqin Li, Wei Li, Yan Yang, Qing Gu, Xing Zhang, Xiaoxuan Wang, Chan Zhu, Dongsheng Chen, Baorui Liu, Juan D. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal transduction and targeted therapy. vol 9. issue 1. 2024-06-06. PMID:38844468. |
the median pfs (mpfs) and os (mos) were 8.8 (95% ci, 8.1-11.6), and 13.7 (95% ci, 12.4 to not reached) months, respectively. |
2024-06-06 |
2024-06-10 |
Not clear |
| Tianlin Xiao, Sheng Hu, Shuang Dong, Qian Cai, Wei Gong, Yang Zhang, Cheng Long, Xiaoyu L. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma. International immunopharmacology. vol 134. 2024-05-11. PMID:38733820. |
similarly, in the real-world setting, non-curative rfa combined with pd-1 blocking and lenvatinib for 12 patients with barcelona clinic liver cancer (bclc) stage c achieve promising results, with 6.9 months (95 % ci: 3.23-15.73) median progression-free survival (mpfs) and 12.7 months (95 % ci: 7.40-19.73) median overall survival (mos). |
2024-05-11 |
2024-05-27 |
mouse |
| Marta Baptista Freitas, Mariana Costa, Andreia Freire Coelho, Pedro Rodrigues Pereira, Manuel Leal, Cristina Sarmento, Lúcia Águas, Miguel Barbos. Sinonasal Adenocarcinoma: Clinicopathological Characterization and Prognostic Factors. Cureus. vol 16. issue 3. 2024-04-15. PMID:38618397. |
papillary and colonic subtypes were associated with higher median progression-free survival (mpfs) than mucinous and solid subtypes (mpfs 37 months, 95% ci, 20.0-54.0, vs. 9 months, 95% ci, 7.15-10.85, p=0.01); the former was also associated with higher median overall survival (mos) (mos 64 months, 95% ci, 37.18-90.81 vs. 14 months, 95% ci, 0-41.58, p=0.02). |
2024-04-15 |
2024-04-17 |
Not clear |
| Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano But. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis. 2024-02-16. PMID:38363410. |
the prognostic impact of the red cell-based score on pfs and os was confirmed in the whole population regardless of the immunotherapy combination used [median pfs (mpfs): 17.4 vs 8.2 months, hr 0.66, 95% ci 0.47-0.94; median os (mos): 42.0 vs 17.3 months, hr 0.60, 95% ci 0.39-0.92; p < 0.001 for both]. |
2024-02-16 |
2024-02-18 |
Not clear |
| Ningning Yan, Sanxing Guo, Ziheng Zhang, Shujing Shen, Xingya L. Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single‑institution experience. Oncology letters. vol 27. issue 3. 2024-02-15. PMID:38357477. |
patients treated with icis demonstrated extended median overall survival (mos) times [23.5 months; 95% confidence interval (ci), 18.524-28.476] compared with patients who did not receive icis (11.2 months; 95% ci, 4.530-18.930) (p<0.001). |
2024-02-15 |
2024-02-17 |
Not clear |
| Natalia M Roshardt Prieto, Patrick Turko, Caroline Zellweger, Thi Dan Linh Nguyen-Kim, Ramon Staeger, Elisa Bellini, Mitchell P Levesque, Reinhard Dummer, Egle Ramelyt. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. Melanoma research. 2023-12-21. PMID:38126339. |
in the 19 enrolled patients, recist showed an overall response rate (orr) of 10%, median progression-free survival of 2.8 months (95% ci 2.5-8.4), and median os (mos) of 18.8 months. |
2023-12-21 |
2023-12-23 |
Not clear |